Roche Reports A "Solid" Third Quarter, But Expects Further EU Pricing Pressure

Roche's sales grew only 2% in the first nine months of 2010, held back by U.S. health care reform and EU price cuts, a decline in Tamiflu sales and adverse currency fluctuations.